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Purpose: To compare the efﬁcacy of lumiracoxib 100 mg od with
placebo and celecoxib 200 mg od in primary knee osteoarthritis
(OA) patients in total population and in age groups <65 and ≥65
Methods: Data from two 13-week, multicenter, randomized,
double-blind, double-dummy, placebo-controlled studies compar-
ing lumiracoxib 100 mg od with celecoxib 200 mg od were
pooled to permit post-hoc combined and subgroup analyses by
age (<65 and ≥65 years) of the prespeciﬁed co-primary end-
points: OA pain intensity in the target knee (0-100 mm VAS),
patient’s global assessment of disease activity (0-100 mm VAS),
and WOMAC™ LK3.1 total score, at study end.
Results: An analysis of the combined data from the two efﬁcacy
studies showed that after 13 weeks of treatment, lumiracoxib 100
mg od (n=1616) was statistically superior to placebo (n=806) for
all three co-primary endpoints (p<0.001). Efﬁcacy of lumiracoxib
100 mg od was similar to celecoxib 200 mg (n=813) for OA
pain intensity in the target knee and WOMAC™ total score and
was statistically signiﬁcantly superior in terms of patient’s global
assessment of disease activity (p=0.044). Of the 3235 patients
in the pooled ITT population, 1894 patients were in the <65
age group [lumiracoxib 100 mg (n=928), placebo (n=477) and
celecoxib 200 mg (n=489)] and 1341 patients were in the ≥65
age group (lumiracoxib 100 mg (n=688), placebo (n=329) and
celecoxib 200 mg (n=324)]. For patients <65 years of age and in
the ≥65 age subgroup, lumiracoxib 100 mg od was statistically
signiﬁcantly superior to placebo and similar to celecoxib for all
three co-primary endpoints (p<0.001) (Table 1).There was no
signiﬁcant treatment by age group interaction for any of the three
co-primary endpoints.
Conclusions: Lumiracoxib provides effective pain relief and im-
provement of functional status in patients with primary knee OA,
with no differences observed in the efﬁcacy endpoints in the two
age groups <65 and ≥65.
Abstract 267 – Table 1. Efﬁcacy of lumiracoxib after 13 weeks of treatment
Efﬁcacy variable Pair wise comparison Total population Age group: <65 Age group: ≥65
Estimated treatment p-value Estimated treatment p-value Estimated treatment p-value
difference (95% CI) difference (95% CI) difference (95% CI)
OA pain Lumiracoxib vs placebo -6.11 (-8.10,-4.12) <0.001 -6.30 (-8.90,-3.69) <0.001 -5.89 (-8.99,-2.79) <0.001
Celecoxib vs placebo -5.20 (-7.50,-2.90) <0.001 -4.36 (-7.34,-1.38) 0.004 -6.45 (-10.07,-2.83) <0.001
Lumiracoxib vs celecoxib -0.91 (-2.90,1.08) 0.368 -1.94 (-4.52,0.65) 0.142 0.56 (-2.56,3.68) 0.725
Patient’s global assessment Lumiracoxib vs placebo -7.28 (-9.24,-5.31) <0.001 -7.50 (-10.07,-4.93) <0.001 -7.03 (-10.08,-3.97) <0.001
of disease activity Celecoxib vs placebo -5.26 (-7.53,-3.00) <0.001 -5.11 (-8.05,-2.18) <0.001 -5.47 (-9.04,-1.89) 0.003
Lumiracoxib vs celecoxib -2.02 (-3.98,-0.06) 0.044 -2.39 (-4.94,0.16) 0.066 -1.56 (-4.63,1.51) 0.320
WOMAC™ total score Lumiracoxib vs placebo -5.64 (-7.04,-4.24) <0.001 -6.00 (-7.83,-4.17) <0.001 -5.17 (-7.34,-3.00) <0.001
Celecoxib vs placebo -4.64 (-6.25,-3.03) <0.001 -4.64 (-6.73,-2.55) <0.001 -4.62 (-7.16,-2.08) <0.001
Lumiracoxib vs celecoxib -1.00 (-2.40,0.39) 0.159 -1.36 (-3.17,0.45) 0.142 -0.55 (-2.74,1.64) 0.622
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PREDICTORS OF DECREASED FUNCTION AND
ACTIVITY LEVEL IN PATIENTS SEEKING TREATMENT
FOR OSTEOARTHRITIS OF THE KNEE
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Purpose: Identifying factors associated with decreased function
and decreased activity may help develop early treatment pro-
grams which can decrease the impact of arthritis. The purpose
of this study was to identify determinants of decreased function,
as determined by Lysholm score, and patient activity level, as
determined by Tegner Activity Level, in patients presenting for
evaluation of osteoarthritis of the knee.
Methods: A cohort of patients (n=862, average age = 59 (range
35 to 92); 45% females, 55% males), who were diagnosed with
OA of the knee on initial exam, was studied prospectively. All
patients had complete demographic, subjective and objective
data from the initial exam. Patient symptoms were graded on
a 4-point scale (none, mild, moderate, severe). The dependent
variables were Lysholm score (0-100) for function. This score has
been correlated with the WOMAC score for osteoarthritis. For
activity, the Tegner Activity level(1-10) was used. Univariate and
multivariable analysis were performed to identify determinants.
Results: Prior surgeries were reported in 58% of the knees, and
80% had joint space narrowing on radiographic examination. For
demographic variables, there were no signiﬁcant associations
(p>0.05) between Lysholm and age, or prior surgery. Lysholm
was higher in males (57 vs 47; p=0.001) and Tegner was higher
in males (3.6 vs 2.8; p=0.004). Tegner was signiﬁcantly as-
sociated (P<0.05) with age (rho=-0.15; p=0.001) and gender.
Tegner was also associated with number of prior surgeries, with
knees operated on 2 or more times having signiﬁcantly lower
scores (P<0.05). For objective variables, there was a signiﬁ-
cant difference (p<0.05) in Lysholm for the presence of joint
space narrowing, extension deﬁcits and ﬂexion deﬁcits. Tegner
level was not associated with joint space narrowing, however, it
was associated with extension and ﬂexion deﬁcits. For subjective
symptoms at initial visit, patients with knee stiffness had signiﬁ-
cantly lower Lysholm scores. (p<0.05) Patients reporting severe
stiffness had an average Lysholm score of 26 points less than
those with no stiffness. Multivariate analysis identiﬁed joint space
narrowing and patient reported stiffness as independent predic-
tors of Lysholm (r2=0.41; p<0.05). Independent predictors of
Tegner activity level were age, gender, patient reported stiffness,
ﬂexion deﬁcit, and Lysholm score (r2=0.37; p<0.05).
Conclusions: Determinants of decreased function and de-
creased activity level in patients seeking treatment for os-
teoarthritis of the knee were established. Patient reported stiff-
ness and range of motion deﬁcit were found to be associated
with both decreased activity level and decreased Lysholm score.
These factors may be important in developing early treatment
